Peripheral blood lymphocytes analysis detects CD100/SEMA4D alteration in systemic sclerosis patients

Autoimmunity

Volumn 44, Issue 5, 2011, Pages 427-436

  Besliu, Alina ^a   Banica, Leontina ^a   Predeteanu, Denisa ^b   Vlad, Violeta ^b   Ionescu, Ruxandra ^c   Pistol, Gina ^a   Opris, Daniela ^c   Berghea, Florian ^c   Stefanescu, Maria ^a   Matache, Cristiana ^a  

^a CANTACUZINO INSTITUTE   (Romania)

^b Sfanta Maria Clinical Hospital   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

B cells; CD100; CD72; Systemic sclerosis; T cells

Indexed keywords

C REACTIVE PROTEIN; CD72 ANTIGEN; CENTROMERE ANTIBODY; SCL 70 ANTIBODY; SEMAPHORIN; SEMAPHORIN 4D; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNE DYSREGULATION; MALE; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

ADULT; ANTIGENS, CD; B-LYMPHOCYTES; CD4-CD8 RATIO; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTES; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEMAPHORINS;

EID: 79960148493     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2010.541171     Document Type: Article

References (51)

1. Guiducci S, Distler O, Distler JH, Matucci-Cerinic M. Mechanisms of vascular damage in SSc-implications for vascular treatment strategies. Rheumatology (Oxford) 2008; 47:v18-v20
2. Denton CP. Renal manifestations of systemic sclerosis-clinical features and outcome assessment. Rheumatology (Oxford) 2008;47:v54-v56
3. Varga J. Systemic sclerosis: an update. Bull NYU Hosp Jt Dis 2008;66:198-202
4. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210 (Pubitemid 351160157)
5. Goh NS, Du Bois RM. Interstitial disease in systemic sclerosis. In: Wells AU, Denton CP, editors. Pulmonary involvement in systemic autoimmune diseases, Vol. 2 (Handbook of Systemic Autoimmune Diseases). Amsterdam: Elsevier BV; 2004. p 181-208
6. Krieg T, Abraham D, Lafyatis R. Fibrosis in connective tissue disease: The role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther 2007;9:S4
7. BurwellT, DelaneyT, Chen C, Connor J, Coyle AJ, Lemaire R. Alterations in both coagulation and fibrinolytic pathways mediate thrombosis in the skin during murine graft-versus-host (GVH)-induced scleroderma. J Immunol 2009;182:48.5
8. Zuber JP, Spertini F. Immunological basis of systemic sclerosis. Rheumatology (Oxford) 2006;45:iii23-iii25 (Pubitemid 44446771)
9. Kawai M, Masuda A, Kuwana M. A CD40-CD154 interaction in tissue fibrosis. Arthritis Rheum 2008;58: 3562-3573
10. Chizzolini C. T lymphocyte and fibroblast interactions: The case of skin involvement in systemic sclerosis and other examples. Springer Semin Immunopathol 1999;21: 431-450 (Pubitemid 30433751)
11. Szegedi A, Czirja?k L, Unkeless JC, Boros P. Serum cytokine and anti-Fc gamma R autoantibody measurements in patients with systemic sclerosis. Acta Derm Venereol 1996; 76:21-23
12. Boin F, De Fanis U, Bartlett SJ, Wigley FM, Rosen A, Casolaro V. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum 2008;58:1165-1174 (Pubitemid 351564020)
13. Romagnani S. T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol 2000;85:9-18; quiz 18, 21
14. Chizzolini C. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol 2008;20:707-712
15. Boin F, Rosen A. Autoimmunity in systemic sclerosis: Current concepts. Curr Rheumatol Rep 2007;9:165-172 (Pubitemid 46932724)
16. Fujimoto M, Sato S. B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 2005;17:746-751 (Pubitemid 41546494)
17. Kikutani H, Kumanogoh A. Semaphorins in interactions between T cells and antigen-presenting cells. Nat Rev Immunol 2003;3:159-167 (Pubitemid 37328693)
18. Bougeret C, Mansur IG, Dastot H, Schmid M, Mahouy G, Bensussan A, Boumsell L. Increased surface expression of a newly identified 150-kDa dimer early after human T lymphocyte activation. J Immunol 1992;148:318-323
19. Billard C, Delaire S, Raffoux E, Bensussan A, Boumsell L. Switch in the protein tyrosine phosphatase associated with human CD100 semaphorin at terminal B-cell differentiation stage. Blood 2000;95:965-972 (Pubitemid 30062719)
20. Mizrahi S, Markel G, Porgador A, Bushkin Y, Mandelboim O. CD100 on NK cells enhance IFNgamma secretion and killing of target cells expressing CD72. PLoS ONE 2007;2:e818
21. Zhu L, Bergmeier W, Wu J, Jiang H, Stalker TJ, Cieslak M, Fan R, Boumsell L, Kumanogoh A, Kikutani H,Tamagnone L, Wagner DD, Milla ME, Brass LF. Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. PNAS 2007;104: 1621-1626 (Pubitemid 46214640)
22. Hall KT, Boumsell L, Schultze JL, Boussiotis VA, Dorfman DM, Cardoso AA, Bensussan A, Nadler LM, Freeman GJ. Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. PNAS 1996;93:11780-11785 (Pubitemid 26347200)
23. Delaire S, Billard C, Tordjman R, Che?dotal A, Elhabazi A, Bensussan A, Boumsell L. Biological activity of soluble CD100. II. Soluble CD100, similarly to H-SemaIII, inhibits immune cell migration. J Immunol 2001;166:4348-4354 (Pubitemid 32233716)
24. Kumanogoh A, Suzuki K, Ch?ng E,Watanabe C, Marukawa S, Takegahara N, Ishida I, Sato T, Habu S, Yoshida K, Shi W, Kikutani H. Requirement for the lymphocyte semaphorin, CD100, in the induction of antigen-specific T cells and the maturation of dendritic cells. J Immunol 2002;169: 1175-1181 (Pubitemid 34809157)
25. Ishida I, Kumanogoh A, Suzuki K, Akahani S, Noda K, Kikutani H. Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: Implications for the regulation of immune and inflammatory responses. Int Immunol 2003;15:1027-1034 (Pubitemid 36987300)
26. Kumanogoh A, Shikina T, Watanabe C, Takegahara N, Suzuki K, Yamamoto M, Takamatsu H, Prasad DV, Mizui M, Toyofuku T, Tamura M, Watanabe D, Parnes JR, Kikutani H. Requirement for CD100-CD72 interactions in fine-tuning of B-cell antigen receptor signaling and homeostatic maintenance of the B-cell compartment. Int Immunol 2005;17:1277-1282 (Pubitemid 41488001)
27. Li DH, Tung JW, Tarner IH, Snow AL, Yukinari T, Ngernmaneepothong R, Martinez OM, Parnes JR. CD72 down-modulates BCR-induced signal transduction and diminishes survival in primary mature B lymphocytes. J Immunol 2006;176:5321-5328
28. Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal A, Winberg ML, Goodman CS, Poo M, Tessier-Lavigne M, Comoglio PM. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999;99:71-80 (Pubitemid 29468631)
29. Kumanogoh A, Watanabe C, Lee I, Wang X, Shi W, Araki H, Hirata H, Iwahori K, Uchida J, Yasui T, Matsumoto M, Yoshida K, Yakura H, Pan C, Parnes JR, Kikutani H. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: A novel mechanism for regulating B cell signaling. Immunity 2000;13:621-631
30. Suzuki K, Kumanogoh A, Kikutani H. Semaphorins and their receptors in immune cell interactions. Nat Immunol 2008;9: 17-23 (Pubitemid 350286199)
31. Wu HJ, Bondada S. CD72, a coreceptor with both positive and negative effects on B lymphocyte development and function. J Clin Immunol 2009;29:12-21
32. Adachi T, Flaswinkel H, Yakura H, Reth M, Tsubata T. The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation. J Immunol 1998;160: 4662-4665 (Pubitemid 28215297)
33. Wu Y, Nadler MJ, Brennan LA, Gish GD, Timms JF, Fusaki N, Jongstra-Bilen J, Tada N, Pawson T, Wither J, Neel BG, Hozumi N. The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1. Curr Biol 1998;8:1009-1017 (Pubitemid 28448073)
34. Shi W, Kumanogoh A, Watanabe C, Uchida J, Wang X, Yasui T, Yukawa K, Ikawa M, Okabe M, Parnes JR, Yoshida K, Kikutani H. The class IV semaphorin CD100 plays nonredundant roles in the immune system: Defective B and T cell activation in CD100-deficient mice. Immunity 2000;13: 633-642
35. Wang X, Kumanogoh A, Watanabe C, Shi W, Yoshida K, Kikutani H. Functional soluble CD100/Sema4D released from activated lymphocytes: Possible role in normal and pathologic immune responses. Blood 2001;97:3498-3504
36. Elhabazi A, Delaire S, Bensussan A, Boumsell L, Bismuth G. Biological activity of soluble CD100. I. The extracellular region of CD100 is released from the surface of T lymphocytes by regulated proteolysis. J Immunol 2001;166:4341-4347 (Pubitemid 32233715)
37. Basile JR, Holmbeck K, Bugge TH, Gutkind JS. MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D. J Biol Chem 2007;282:6899-6905 (Pubitemid 47100895)
38. Chabbert-de Ponnat I, Marie-Cardine A, Pasterkamp RJ, Schiavon V, Tamagnone L, Thomasset N, Bensussan A, Boumsell L. Soluble CD100 functions on human monocytes and immature dendritic cells require plexin C1 and plexin B1, respectively. Int Immunol 2005;17:439-447 (Pubitemid 40568119)
39. Hitomi Y, Tsuchiya N, Kawasaki A, Ohashi J, Suzuki T, Kyogoku C, Fukazawa T, Bejrachandra S, Siriboonrit U, Chandanayingyong D, Suthipinittharm P, Tsao BP, Hashimoto H, Honda Z, Tokunaga K. CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B. Hum Mol Genet 2004;13: 2907-2917 (Pubitemid 39585223)
40. Nakano S, Morimoto S, Suzuki J, Mitsuo A, Nakiri Y, Katagiri A, Nozawa K, Amano H, Tokano Y, Hashimoto H, Takasaki Y. Down-regulation of CD72 and increased surface IgG on B cells in patients with lupus nephritis. Autoimmunity 2007;40:9-15 (Pubitemid 46332417)
41. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23: 581-590
42. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N,Wollheim F. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-205 (Pubitemid 18073738)
43. Czirja?k L, Nagy Z, Aringer M, Riemekasten G, Matucci-Cerinic M, Furst DE; EUSTAR. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007;66: 966-969 (Pubitemid 46999803)
44. Marie I, Dominique S, Levesque H, Ducrotte P, Denis P, Hellot MF, Courtois H. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001;45:346-354 (Pubitemid 32738740)
45. Li M, O?Sullivan KM, Jones LK, Semple T, Kumanogoh A, Kikutani H, Holdsworth SR, Kitching AR. CD100 enhances dendritic cell and CD4? cell activation leading to pathogenetic humoral responses and immune complex glomerulonephritis. J Immunol 2006;177:3406-3412 (Pubitemid 44277861)
46. Basile JR, Afkhami T, Gutkind JS. Semaphorin 4D/plexin-B1 induces endothelial cell migration through the activation of PYK2, Src, and the phosphatidylinositol 3-kinase-Akt pathway. Mol Cell Biol 2005;25:6889-6898 (Pubitemid 41105890)
47. Radstake TR, van Bon L, Broen J, Hussiani A, Hesselstrand R, Wuttge DM, Deng Y, Simms R, Lubberts E, Lafyatis R. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 2009;4:e5903
48. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000;165:6635-6643
49. Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S. CD19 regulates skin and lung fibrosis via toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008;172:1650-1663 (Pubitemid 351793356)
50. Tsuchiya N, Kuroki K, Fujimoto M, Murakami Y, Tedder TF, Tokunaga K, Takehara K, Sato S. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 2004;50:4002-4007 (Pubitemid 39643949)
51. Giraudon P, Vincent P, Vuaillat C, Verlaeten O, Cartier L, Marie-Cardine A, Mutin M, Bensussan A, Belin MF, Boumsell L. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J Immunol 2004;172: 1246-1255 (Pubitemid 38113788)